StockNews.com began coverage on shares of MediWound (NASDAQ:MDWD – Get Rating) in a report released on Saturday morning. The firm issued a sell rating on the biopharmaceutical company’s stock. Several other research firms have also commented on MDWD. Aegis reduced their price target on shares of MediWound from $9.00 to $7.00 and set a buy […]
MediWound (NASDAQ:MDWD – Get Rating) had its price objective trimmed by Aegis from $9.00 to $7.00 in a report published on Monday, Benzinga reports. The firm currently has a buy rating on the biopharmaceutical company’s stock. A number of other brokerages also recently issued reports on MDWD. StockNews.com began coverage on shares of MediWound in […]
Zacks Investment Research cut shares of MediWound (NASDAQ:MDWD – Get Rating) from a buy rating to a hold rating in a research report report published on Saturday morning, Zacks.com reports. According to Zacks, “MediWound Ltd. is a biotechnology niche specialty company. It is focused on developing, manufacturing and commercializing products that address unmet needs in […]
MediWound (NASDAQ:MDWD – Get Rating) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($0.15) EPS for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.15), MarketWatch Earnings reports. MediWound had a negative return on equity of 332.31% and a negative net margin of 44.58%. During the same quarter last year, the […]
Brokerages forecast that MediWound Ltd. (NASDAQ:MDWD – Get Rating) will post sales of $5.65 million for the current quarter, Zacks reports. Two analysts have issued estimates for MediWound’s earnings, with estimates ranging from $5.60 million to $5.70 million. MediWound reported sales of $6.67 million in the same quarter last year, which would suggest a negative […]